Shares of local generic drug giant Mylan shot higher Wednesday after the company won Food and Drug Administration approval for its generic copy of GlaxoSmithKline’s Advair.
The inhaler is used to treat asthma and chronic obstructive pulmonary disease.
Mylan had suffered a number of setbacks on the road to approval, with the FDA rejecting its drug application for a second time in June. In October, Mylan had told analysts that approval was imminent.
Shares added $2.05, or 7 percent, to close at $30.82 Wednesday.
News of the approval — which is the first generic for one of the most commonly prescribed asthma and COPD inhalers in the U.S. — appeared on the FDA’s drug approvals web page Wednesday afternoon..
For the third quarter, Mylan’s revenue had fallen 4 percent to $2.86 billion, dragged down by lower sales of the EpiPen allergy shot and a restructuring at the company’s flagship plant in Morgantown, W.Va.
Profits for the third quarter, excluding special items, rose 10 percent.
In the second quarter, Mylan announced its board was conducting a strategic review aimed at “unlocking the true value” of the company, which is run from executive offices in Cecil. Since then, Mylan has not provided an update on the matter.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.